Key Drivers
- Margin Strength
- Cash Flow
- Leverage Risk
AIAI Summary
MIRM has evolved from a single-product Livmarli story into a broader rare-liver-disease platform, but the investment now hinges on whether clinical wins in volixibat/brelovitug and continued LIVMARLI growth can scale fast enough to justify its rich valuation while offsetting rising खर्च and dilution from financing.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Cash Flow
- •Leverage Risk
MIRM still benefits from exceptional gross margins and a solid balance sheet, but Q1 2026 saw a sharp earnings and cash-flow deterioration alongside rising leverage, leaving the stock expensive for its weak profitability.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance rejection
- •Short-term overbought
MIRM improved in late April and early May with higher lows and a breakout above $100, but the failed push into the $110-$111 area and sharp reversal to $102.19 suggest near-term caution until it reclaims that resistance.
Sharp run from $100 to $111.39 was followed by a quick reversal to $102.19, signaling volatility and possible overextension
Sentiment & News
Key News Insights:
- •Late-stage wins
- •Revenue beat
- •Balance-sheet reset
Mirum Pharmaceuticals is showing broad momentum with positive late-stage liver-disease trial results, stronger-than-expected sales, and a $600 million convertible notes refinancing to support growth.
This news is likely supportive for the stock as it improves pipeline confidence, strengthens the commercial outlook, and adds financial flexibility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings